Skip to main content

Table 4 Clinical backgrounds between MACE and no-MACE group of CYP2C19*2 carriers

From: Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study

Clinical backgrounds Total (n = 100) MACE (n = 43) No-MACE (n = 57) P value
Male sex, n (%) 89 (89.0) 40 (93.0) 49 (86.0) 0.343
Age(years, mean ± SD) 58.0 ± 8.8 58.5 ± 8.6 57.6 ± 9.0 0.633
BMI (kg/m2, mean ± SD) 28.2 ± 3.9 28.9 ± 3.3 27.7 ± 4.2 0.122
Alcohol intake, n (%) 18 (18.0) 7 (16.3) 11 (19.3) 0.697
Smoking, n (%) 42 (42.0) 18 (41.9) 24 (42.1) 0.980
SBP (mmHg, mean ± SD) 133.3 ± 21.7 137.2 ± 26.6 131.5 ± 24.8 0.174
DBP (mmHg, mean ± SD) 79.5 ± 13.7 80.1 ± 12.7 79.0 ± 14.5 0.664
TG (mg/dL) 1.65 ± 0.78 1.67 ± 0.56 1.64 ± 0.73 0.887
LDL-C (mg/dL) 2.50 ± 0.90 2.43 ± 0.93 2.57 ± 0.88 0.426
HDL-C (mg/dL) 0.85 ± 0.20 0.85 ± 0.16 0.86 ± 0.23 0.684
TC (mg/dL) 3.98 ± 1.01 3.94 ± 0.98 4.0 ± 1.04 0.731
ALT (IU/L) 35.8 ± 18.7 30.5 ± 11.9 40.0 ± 17.7 0.205
AST (IU/L) 39.7 ± 16.0 35.2 ± 15.6 43.1 ± 16.4 0.375
Creatinine (μmol/ L) 72.1 ± 19.0 71.9 ± 25.2 72.3 ± 12.4 0.926
UA (μmol/ L) 321.1 ± 61.9 320.0 ± 56.0 322.0 ± 66.8 0.914
BG (mmol/ L) 6.52 ± 2.61 6.79 ± 2.83 6.32 ± 2.45 0.375
Clinical presentation, n (%)
 Unstable angina 49 (49.0) 20 (46.5) 29 (50.9) 0.665
 STEMI 32 (32.0) 13 (30.2) 19 (33.3) 0.742
 NSTEMI 24 (24.0) 13 (30.2) 11 (19.3) 0.205
Final treatment, n (%)     
 PCI 82 (82.0) 38 (88.4) 44 (77.2) 0.15
 CABG 2 (2.0) / 2 (3.5) 0.505
 Medical treatment only 17 (17.0) 5 (11.6) 12 (21.1) 0.214
Comorbidities, n%
 Hypertension 57 (57.0) 32 (66.7) 30 (48.4) 0.067
 Fatty liver 26 (26.0) 14 (32.6) 12 (21.1) 0.194
 Diabetes mellitus 37 (37.0) 20 (46.5) 17 (29.8) 0.087
 Dyslipidemia 83 (83.0) 37 (86.0) 46 (80.7) 0.481
History, n (%)     
 Previous MI 23 (23.0) 9 (20.9) 14 (24.6) 0.669
 Previous PCI 13 (13.0) 5 (11.6) 8 (14.0) 0.723
 Previous CABG 1 (1.0) / 1 (1.8) 1.0
Concomitant medication, n%
 Statin 96 (96.0) 41 (95.3) 55 (96.5) 1.0
 PPI 44 (44.0) 16 (37.2) 28 (49.1) 0.235
 CCB 26 (26.0) 12 (27.9) 14 (24.6) 0.706
 β-Blocker 82 (82.0) 37 (86.0) 45 (78.9) 0.36
 Diuretics 25 (25.0) 11 (25.6) 14 (24.6) 0.907
 ARB or ACEI 77 (77.0) 33 (76.7) 44 (77.2) 0.958
  1. BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TG triglycerides, LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol, TC total cholesterol, ALT glutamic-pyruvic transaminase, AST glutamic-oxalacetic transaminase, UA uric acid, BG blood glucose, NSTEMI non-ST-segment elevation myocardial infarction, STEMI ST-segment elevation myocardial infarction, MACE major adverse cardiac events, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, ARB angiotensin receptor blocker, ACEI angiotensin antagonist inhibitor, CCB calcium channel blocker, PPI proton pump inhibitor